Glucotrack FY2024 net loss $22.6M; completes first human CBGM study, expects IDE in Q4 2025

Glucotrack, Inc.

2025-Q1 EPS reported -$0.67

Net loss of $22.6M vs $7.1M in 2023; R&D expense $9.5M (+$4.8M YoY) on increased product development activities.
Cash $5.6M at Dec 31, 2024; pro forma $11.9M after Q1 2025 offerings; raised $16.3M since Nov 2024.
First human clinical study of CBGM met primary endpoint with no device-related serious adverse events.
Appointed new CFO, VP Regulatory, VP Clinical Ops; expanded Medical Advisory Board.
Anticipates IDE approval from FDA in Q4 2025; long-term study in Australia expected Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.